Higher dose of warfarin for patients with pulmonary embolism complicated by obstructive sleep apnea hypopnea syndrome

Abstract Background The concomitant prevalence of obstructive sleep apnea hypopnea syndrome (OSAHS) and pulmonary embolism (PE) is strikingly high, and therefore we studied the patients with PE to determine whether those who had OSHAS required greater warfarin doses to achieve a therapeutic internat...

Full description

Saved in:
Bibliographic Details
Published in:Heart & lung 2014-07, Vol.43 (4), p.358-362
Main Authors: Jiang, Xie, MD, Yongxiang, Wei, MD, Wei, Zhang, MD, Xiangfeng, Zhang, MD, Jie, Li, MD, Achakzai, Rehmatullah, MB, Shuang, Liu, MD
Format: Article
Language:English
Subjects:
Aged
Anticoagulants
Body Weight
Cardiology
Cardiovascular
Coagulation
Critical Care
Drug dosages
Embolisms
Female
Humans
International Normalized Ratio
Male
Medical imaging
Middle Aged
Obstructive sleep apnea hypopnea syndrome
Polysomnography
Prospective Studies
Pulmonary embolism
Pulmonary Embolism - complications
Pulmonary Embolism - drug therapy
Pulmonary/Respiratory
Risk Factors
Sleep apnea
Sleep Apnea, Obstructive - complications
Warfarin
Warfarin - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The concomitant prevalence of obstructive sleep apnea hypopnea syndrome (OSAHS) and pulmonary embolism (PE) is strikingly high, and therefore we studied the patients with PE to determine whether those who had OSHAS required greater warfarin doses to achieve a therapeutic international normalized ratio (INR). Methods By using computer tomographic pulmonary angiography or pulmonary angiography, we identified and recruited 97 patients with PE and all underwent polysomnography. Warfarin was initiated at a dose of 3 mg/day and modified to adjust the INR to the range of 2.0–3.0. Results OSAHS patients ( n  = 32) required a significantly higher dose of warfarin than their non-OSAHS counterparts (5.01 mg vs 3.61 mg, P  
ISSN:0147-9563
1527-3288
DOI:10.1016/j.hrtlng.2014.04.005